JPWO2022167457A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022167457A5 JPWO2022167457A5 JP2023546486A JP2023546486A JPWO2022167457A5 JP WO2022167457 A5 JPWO2022167457 A5 JP WO2022167457A5 JP 2023546486 A JP2023546486 A JP 2023546486A JP 2023546486 A JP2023546486 A JP 2023546486A JP WO2022167457 A5 JPWO2022167457 A5 JP WO2022167457A5
- Authority
- JP
- Japan
- Prior art keywords
- oxygen
- compound
- nitrogen
- independently selected
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 100
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 72
- 125000005842 heteroatom Chemical group 0.000 claims description 72
- 229910052757 nitrogen Inorganic materials 0.000 claims description 72
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 72
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 72
- 229910052760 oxygen Inorganic materials 0.000 claims description 72
- 239000001301 oxygen Chemical group 0.000 claims description 72
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 68
- 229910052717 sulfur Chemical group 0.000 claims description 68
- 239000011593 sulfur Chemical group 0.000 claims description 68
- 229920006395 saturated elastomer Polymers 0.000 claims description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 125000001931 aliphatic group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 20
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 12
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052805 deuterium Inorganic materials 0.000 claims description 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 8
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 8
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 claims description 6
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- -1 R z Chemical class 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010030216 Oesophagitis Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 208000030172 endocrine system disease Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000006881 esophagitis Diseases 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 125000005549 heteroarylene group Chemical group 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 230000002314 neuroinflammatory effect Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 239000000523 sample Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144720P | 2021-02-02 | 2021-02-02 | |
| US63/144,720 | 2021-02-02 | ||
| PCT/EP2022/052419 WO2022167457A1 (en) | 2021-02-02 | 2022-02-02 | Gpr84 antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505571A JP2024505571A (ja) | 2024-02-06 |
| JPWO2022167457A5 true JPWO2022167457A5 (https=) | 2025-02-10 |
| JP2024505571A5 JP2024505571A5 (https=) | 2025-02-10 |
Family
ID=80683145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546486A Pending JP2024505571A (ja) | 2021-02-02 | 2022-02-02 | Ｇｐｒ８４アンタゴニストおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230113202A1 (https=) |
| EP (1) | EP4288427A1 (https=) |
| JP (1) | JP2024505571A (https=) |
| KR (1) | KR20230153387A (https=) |
| CN (1) | CN117098757A (https=) |
| AU (1) | AU2022216810A1 (https=) |
| BR (1) | BR112023015590A2 (https=) |
| CA (1) | CA3206501A1 (https=) |
| IL (1) | IL304701A (https=) |
| MX (1) | MX2023009060A (https=) |
| TW (1) | TW202246247A (https=) |
| WO (1) | WO2022167457A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| JP7705966B2 (ja) * | 2021-06-21 | 2025-07-10 | 武漢人福創新薬物研発中心有限公司 | Ｇｐｒ８４アンタゴニストとしての三環式化合物 |
| JP2025527247A (ja) * | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用 |
| IL318575A (en) * | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF |
| CN115785010A (zh) * | 2022-11-23 | 2023-03-14 | 湖南大学 | 一类硫代1,2,3-三氮唑及其高效合成方法 |
| CN118077649B (zh) * | 2024-02-29 | 2024-09-10 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂构建动脉粥样硬化小鼠模型的方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CA2621144A1 (en) | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| WO2007143597A2 (en) * | 2006-06-05 | 2007-12-13 | Novartis Ag | Organic compounds |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2185537A1 (en) * | 2007-08-02 | 2010-05-19 | Pfizer Inc. | Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| EP3698794A1 (en) * | 2009-11-06 | 2020-08-26 | Aerpio Therapeutics, Inc. | Compositions and methods for treating colitis |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP2900665B1 (en) * | 2012-09-28 | 2018-01-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| US9315494B2 (en) | 2012-11-08 | 2016-04-19 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| WO2014113485A1 (en) * | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| SI2970255T1 (sl) | 2013-03-14 | 2017-12-29 | Galapagos Nv | Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj |
| EP3080131B1 (en) | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| WO2015131080A1 (en) | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2019060693A1 (en) * | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| WO2019067702A1 (en) * | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
-
2022
- 2022-02-02 EP EP22708396.1A patent/EP4288427A1/en active Pending
- 2022-02-02 CN CN202280025675.4A patent/CN117098757A/zh active Pending
- 2022-02-02 AU AU2022216810A patent/AU2022216810A1/en active Pending
- 2022-02-02 US US17/649,752 patent/US20230113202A1/en active Pending
- 2022-02-02 KR KR1020237029903A patent/KR20230153387A/ko active Pending
- 2022-02-02 JP JP2023546486A patent/JP2024505571A/ja active Pending
- 2022-02-02 WO PCT/EP2022/052419 patent/WO2022167457A1/en not_active Ceased
- 2022-02-02 BR BR112023015590A patent/BR112023015590A2/pt unknown
- 2022-02-02 CA CA3206501A patent/CA3206501A1/en active Pending
- 2022-02-02 MX MX2023009060A patent/MX2023009060A/es unknown
- 2022-02-07 TW TW111104433A patent/TW202246247A/zh unknown
-
2023
- 2023-07-24 IL IL304701A patent/IL304701A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100383139C (zh) | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 | |
| JP7735505B2 (ja) | Ｃｏｔモジュレーター及びその使用方法 | |
| JP2019514883A5 (https=) | ||
| JP2019514876A5 (https=) | ||
| JP2019519476A5 (https=) | ||
| JP2019514882A5 (https=) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2021523225A5 (https=) | ||
| CN108727378A (zh) | 新型异喹啉类化合物及其医药用途 | |
| RU2002127682A (ru) | Замещенные бета-карболины | |
| JP2025516367A (ja) | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 | |
| CN112824410A (zh) | 氮杂七元环类抑制剂及其制备方法和应用 | |
| JP2016513702A (ja) | Ｐ２ｘ７調節物質 | |
| KR102755652B1 (ko) | 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도 | |
| JP7604018B2 (ja) | 化合物、その薬学的に許容される塩又は立体異性体、及びその使用 | |
| JPWO2022167457A5 (https=) | ||
| EP3209652A1 (en) | Tricyclic atropisomer compounds | |
| JPWO2019213445A5 (https=) | ||
| CN109180681B (zh) | 一种dna毒性二聚体化合物 | |
| JP2008504303A5 (https=) | ||
| CN114981273A (zh) | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 | |
| WO2021121420A1 (zh) | 苯并吡唑类化合物及其中间体、制备方法和应用 | |
| JPWO2021207530A5 (https=) | ||
| JPWO2021207550A5 (https=) | ||
| JPWO2021076688A5 (https=) |